1. Home
  2. LMAT vs NRIX Comparison

LMAT vs NRIX Comparison

Compare LMAT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$83.45

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$18.86

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
NRIX
Founded
1983
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
LMAT
NRIX
Price
$83.45
$18.86
Analyst Decision
Buy
Strong Buy
Analyst Count
6
13
Target Price
$101.83
$26.77
AVG Volume (30 Days)
188.5K
1.9M
Earning Date
11-06-2025
01-27-2026
Dividend Yield
0.95%
N/A
EPS Growth
27.40
N/A
EPS
2.32
N/A
Revenue
$240,866,000.00
$83,687,000.00
Revenue This Year
$15.17
$58.38
Revenue Next Year
$9.07
N/A
P/E Ratio
$36.21
N/A
Revenue Growth
13.07
48.32
52 Week Low
$71.42
$8.18
52 Week High
$105.55
$22.50

Technical Indicators

Market Signals
Indicator
LMAT
NRIX
Relative Strength Index (RSI) 43.71 63.87
Support Level $82.52 $19.02
Resistance Level $85.21 $22.50
Average True Range (ATR) 2.32 1.20
MACD 0.03 -0.07
Stochastic Oscillator 33.21 44.60

Price Performance

Historical Comparison
LMAT
NRIX

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: